

Fax Page 1 To:

Yakima Health District

(509) 381-3526 (Confidential FAX line)

CONFIDENTIAL SEXUALLY TRANSMITTED INFECTION CASE REPORT
Report STIs within 3 work days (WAC 246-101-101/301)

Adapted from WA DOH Form 347-102

PATIENT INFO	PATIENT INFORMATION														
LAST NAME			FIRST NAME				MIDDLE NAME D			DATE OF BIRTH					
											мо		DAY		YR
ADDRESS (Unhoused or unstably housed in the			n the pas	e past 3 months) CITY							STATE		ZIP COD	E	
TELEPHONE EMAIL			ENGLISH SPEAKING? ☐ Yes				G? 🗌 Yes 🔲 N	No *instructions on pg. 3 DIAGNOSIS DATE							
()				Pi	refer	red Langi	uage	e (Code*: L)	P8. 5	M	o	DA	Y	YR
SEX ASSIGNED	GENDER IDENT	TITY		ETHNICIT	Υ			RACE CATEGO	RY (ch	eck all t	that a	pply)*:			structions on page 3
AT BIRTH ☐ Male ☐ Transgend				MITE - Thispathic of Lathrayovx -				☐ White ☐ Asian ☐ Other							
☐ Male ☐ Female						nic		American I	ndian /	Alaska	Nativ	/e		Unkn	
☐ Intersex				Refused			☐ Native Hawaiian / O			Other	Pacifi	c Islande	r	☐ Refus	ed
Refused Genderqueer Refused				EXTENDED RACE COL				DE(S)*	DE(S)*: R R R R						
CURRENTLY	REASON FOR EX	XAM (check one):	GENDE	ER OF SEX	PAR	TNERS (c	heck	all that apply):	HIV S	TATUS	;	*Submit HIV	/AIDS (Case Report	CURRENTLY
I	PREGNANT? Exposed to I		☐ Mal	_ 0					a.o p o o			ON PrEP?			
☐ Yes	Symptomatic	· —		emale				- I			Yes				
□ No □ Unk. □ NA	☐ Routine Exar	()		onbinary / □ Other enderqueer □ Unknow			I ~						□ No □ NA		
DIAGNOSIS - E	DISFASE			10.01.40.00										,	
GONORRHEA (I										SYF	HILIS				
DIAGNOSIS (che	eck one)	SITES (all that a	pply):	TREATMENT (check all prescribed):				scribed):		STA	STAGE (check one):				
Asymptomati		☐ Cervix		☐ Ceftriaxone: ☐ 250 mg ☐ 500 mg ☐ 1 g					☐ Primary (Chancre, etc.)						
	, Uncomplicated matory Disease	¦ ☐ Urethra □ ☐ Urine		☐ Cefixime: ☐ 400 mg ☐ 800 mg					☐ Secondary (Rash, etc.) ☐ Early Latent (< 1 year)						
Ophthalmia	natory Discuse	Rectum		☐ Azithromycin: ☐ 1 g ☐ 2 g ☐ Doxycycline: ☐ 100 mg BID x 7 days					Unknown Duration or Late						
☐ Disseminated		☐ Pharynx		Gentamicin: 240 mg					☐ Congenital						
☐ Other Compli	cations:			☐ Gemifloxacin: ☐ 320 mg				МА	MANIFESTATIONS (check all that apply):						
Date Tested:		i □ Othor		Other: Date Prescribed:					☐ Neurologic ☐ Otic ☐ Ocular ☐ Tertiary						
CHLAMYDIA (la	h confirmed)			Date Presi	cribe	u				ТО	- ATR/	ENT /ch	ock c		
DIAGNOSIS (che		SITES (all that a	pply): i	TREATMENT (check all prescribed):					TREATMENT (check one): Bicillin L - A: 2.4 MU IM x 1						
☐ Asymptomat	-	☐ Cervix		☐ Azithromycin: ☐ 1 g				Dici	□ 2.4 MU IM x 3						
	, Uncomplicated	☐ Urethra		☐ Doxycycline: ☐ 100 mg BID x 7 days				Dox	Doxycycline: 100 mg BID x 14 days						
☐ Pelvic Inflammatory Disease☐ Ophthalmia		☐ Urine		☐ Levofloxacin: ☐ 500 mg daily x 7 days ☐ Other:					☐ 100 mg BID x 28 days				8 days		
☐ Other Complications:		☐ Rectum☐ Pharynx		Utner:				Benzathine							
		☐ Vagina						PCN	PCN-G:				g IM x 3		
☐ Ocula			Data Drassvikadu					Aqueous							
Date Tested:		Other:		Date Prescribed:OTHER DISEASES					Crystalline for 10-14 days Penicillin G:						
DIAGNOSIS	-^	LABORATORY CO	NFIRMAT				LJ			Oth	er: _				
☐ Genital (initial infection only)				Granuloma Inguin			nale								
□ Neonatal □ No □ Lymphogranuloma Venereum □ Date Prescribed: PARTNER TREATMENT PLAN (check one or more options)															
		•							·· - · · · · · · ·			-1 4 - 41			/:- - 2
Providers should manage partner treatment by either treating partners in-person or by prescribing medication for patients to give to their sex partners (see side 2 for additional information).															
for additional information). _ In-person evaluation - Number of partners treated following medical evaluation:															
Patient-delivered treatment* - Number of partners for whom provider prescribed or provided expedited partner therapy (EPT) medication pack to be delivered by the patient to their partner(s): *Patient-delivered treatment is not recommended for men who have sex with men or patients with syphilis															
REPORTING CLINIC INFORMATION															
DATE	DATE FACILITY NAME DIAGNOSING CLINICIAN														
ADDRESS						CITY				S	TATE		Z	IP	
PERSON COMPLETING FORM				TELEP	L NOH' I	IE.			E	MAIL					

PARTNER MANAGEMENT PLAN INSTRUCTIONS

Gonorrhea or Chlamydia Infection: Partner Treatment

All partners should be treated as if they are infected.

The Washington State Department of Health strongly encourages providers to take responsibility to ensure partner treatment for heterosexuals, by examining and treating all patient's sex partners from the previous 60 days.

If an examination is not possible, providers should offer medication for all sex partners whom patients are able to contact.

Yakima Health District may be able to provide free medication to your patient to give their partner(s), if resources permit. Please contact your local health jurisdiction to report cases and inquire about partner management resources, possibly including EPT medications.

Yakima Health District recommends you refer all **MSM patients** and **all patients with syphilis or newly diagnosed HIV** to the health department for help notifying partners to ensure that partners receive medication; the opportunity to test for HIV, syphilis, gonorrhea, and chlamydia; and evaluation for HIV Pre-Exposure Prophylaxis (PrEP). Please inform the patient that the health department will contact them to assist with partner notification.

Although the Health Department requests that you refer patients with these risks to us, we also ask that you make every effort to help patients assure that their partners are treated.

Complete the partner management plan on the Confidential Sexually Transmitted Infection Case Report FAX form to define a partner management plan.

For copies of this case report or questions on how to fill it out, call the Yakima Health District: (509) 249-6541.

Other STIs: Partner Treatment

All patients with infectious syphilis, chancroid, LGV, or granuloma inguinale are routinely contacted by public health staff. Patients diagnosed with genital herpes should be advised to notify their sex partners and should be informed that their partners should contact their provider for testing. Per CDC treatment guidelines, sex partners of patients who are diagnosed with early syphilis (primary, secondary, or early latent) and may be incubating disease should be treated regardless of test results. Alternative treatment for penicillin allergy among non-pregnant patients, such as an appropriate dosage of doxycycline, can also be found in the guidelines.

RECOMMENDED REGIMENS FOR ANTIMICROBIALS LISTED ON REPORTS*

GONORRHEA -- Uncomplicated

Ceftriaxone 500 mg IM as a single dose for persons weighing < 150 kg (330 lbs), or 1 g IM as a single dose for persons weighing > 150 kg (330 lbs) †

Alternatives for uncomplicated infections of the cervix, urethra, or rectum: ‡

Gentamicin 240 mg IM as a single dose PLUS azithromycin 2 g PO as a single dose $\bf OR$ Cefixime 800 mg orally as a single dose †

- † If treating with ceftriaxone or cefixime, and chlamydia infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg PO BID for 7 days. During pregnancy, azithromycin 1 g PO as a single dose is recommended to treat chlamydia.
- [‡] Ceftriaxone is the only recommended treatment for pharyngeal gonorrhea. Consult an infectious disease provider or other STI expert for assistance if alternative treatment is required.

CHLAMYDIA -- Uncomplicated

Doxycycline 100 mg PO BID for 7 days **OR** Azithromycin 1g PO as a single dose

Alternatives:

Erythromycin (base) 500 mg PO QID for 7 days OR

Ethylsuccinate 800 mg PO QID for 7 days OR

Ofloxacin 300 mg PO BID for 7 days OR

Levofloxacin 500 mg PO for 7 days

SYPHILIS -- PRIMARY, SECONDARY, OR EARLY LATENT (<1 YEAR)

Benzathine penicillin G 2.4 million units IM in a single dose

SYPHILIS -- LATE OR UNKNOWN DURATION

Benzathine penicillin G 2.4 million units IM for 3 doses at 1 week intervals

DOH 347-102, updated 12/14/2022. For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).

^{*} Refer to "STD Diagnostic and Treatment Guidelines" or the Centers for Disease Control and Prevention's (CDC's) website (https://www.cdc.gov/std/treatment/default.htm) for further information on treating pregnant patients, infections of the pharynx, patients with allergies, treatment of infants, and other details.

List of Preferred Languages:

Instructions: Complete the Preferred Language section if the patient's preferred language is not English. Patient's preferred language shall be identified by the patient and reported using one of the below categories.

Language Identity Codes:

(L01) Amharic	(L18) Karen	(L35) Sign languages
(L02) Arabic	(L19) Khmer/Cambodian	(L36) Somali
(LO3) Balochi/Baluchi	(L20) Kinyarwanda	(L37) Spanish/Castilian
(L04) Burmese	(L21) Korean	(L38) Swahili/Kiswahili
(L05) Cantonese	(L22) Kosraean	(L39) Tagalog
(L06) Chinese (unspecified)	(L23) Lao	(L40) Tamil
(L07) Chamorro	(L24) Mandarin	(L41) Telugu
(L08) Chuukese	(L25) Marshallese	(L42) Thai
(L09) Dari	(L26) Mixteco	(L43) Tigrinya
(L10) Farsi/Persian	(L27) Nepali	(L44) Ukrainian
(L11) Fijian	(L28) Oromo	(L45) Urdu
(L12) Filipino/Pilipino	(L29) Panjabi/Punjabi	(L46) Vietnamese
(L13) French	(L30) Pashto	(L77) Other language
(L14) German	(L31) Portuguese	(L88) Patient declined to respond
(L15) Hindi	(L32) Romanian/Rumanian	(L99) Unknown

(L33) Russian

(L34) Samoan

Race Category and Identity Instructions:

Instructions: The patient's race may either be reported in the general Race Category section or the Extended Race section on page 1 of the case report. When completing the Extended Race section, please report using the codes provided in the list below. If the patient self-identifies as more than one race, each race code shall be reported within the extended race section. Unknown race can be documented within either one of the race sections.

Extended Race Codes:

(L16) Hmong

(L17) Japanese

(R01) Afghan	(R22) Fijian	(R43) Mexican/Mexican American	(R64) Tongan
(R02) Afro-Caribbean	(R23) Filipino	(R44) Middle Eastern	(R65) Ugandan
(R03) Alaska Native	(R24) First Nations	(R45) Mien	(R66) Ukrainian
(R04) American Indian	(R25) Guamanian or Chamorro	(R46) Moroccan	(R67) Vietnamese
(R05) Arab	(R26) Hmong/Mong	(R47) Native Hawaiian	(R68) White
(R06) Asian	(R27) Indigenous-Latina/o/x	(R48) Nepalese	(R69) Yemeni
(R07) Asian Indian	(R28) Indonesian	(R49) North African	(R77) Other race
(R08) Bamar/Burman/Burmese	(R29) Iranian	(R50) Oromo	(R99) Unknown
(R09) Bangladeshi	(R30) Iraqi	(R51) Pacific Islander	
(R10) Bhutanese	(R31) Japanese	(R52) Pakistani	
(R11) Black or African American	(R32) Jordanian	(R53) Puerto Rican	
(R12) Central American	(R33) Karen	(R54) Romanian/Rumanian	
(R13) Cham	(R34) Kenyan	(R55) Russian	
(R14) Chicana/o or Chicanx	(R35) Khmer/Cambodian	(R56) Samoan	
(R15) Chinese	(R36) Korean	(R57) Saudi Arabian	
(R16) Congolese	(R37) Kuwaiti	(R58) Somali	
(R17) Cuban	(R38) Lao	(R59) South African	
(R18) Dominican	(R39) Lebanese	(R60) South American	
(R19) Egyptian	(R40) Malaysian	(R61) Syrian	
(R20) Eritrean	(R41) Marshallese	(R62) Taiwanese	
(R21) Ethiopian	(R42) Mestizo	(R63) Thai	